中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 10
Oct.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(10): 2104-2108

Role of statins in chronic liver disease

DOI: 10.12449/JCH241029
  • 1.

    Central Laboratory，The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine，Chengdu 610072，China

  • 2.

    School of Clinical Medicine，Chengdu University of Traditional Chinese Medicine，Chengdu 610072，China

Research funding:

General Project of National Natural Science Foundation of China (82274323)

More Information
  • Corresponding author: LI Hui， 1400124746@qq.com （ORCID： 0000-0002-5919-1396）
  • Received Date: 2024-02-18
  • Accepted Date: 2024-04-17
  • Published Date: 2024-10-25
    Abstract
  • Chronic liver disease is the “devil’s trilogy” in which the liver progresses from inflammation and fibrosis to liver cirrhosis and hepatocellular carcinoma， which poses a great challenge for hepatologists worldwide. Statins have played a significant role in the treatment of cardiovascular diseases and hyperlipidemia since their introduction， and in recent years， they have also demonstrated the potential to improve hepatic steatosis， exert an anti-inflammatory effect， regulate the phenotype of hepatic stellate cells， reduce portal venous pressure， and improve hepatic microcirculation in chronic liver disease. This article reviews the latest advances in the basic and clinical studies of statins in chronic liver disease， in order to provide new insights into the research， prevention， and treatment of chronic liver disease.

     

    • FullText(HTML)
  • loading
    • References(47)
  • [1]
    GERMAN CA, LIAO JK. Understanding the molecular mechanisms of statin pleiotropic effects[J]. Arch Toxicol, 2023, 97( 6): 1529- 1545. DOI: 10.1007/s00204-023-03492-6.
    [2]
    LI Z, WEI D, WAN MX, et al. Research progress on drug-induced liver injury induced by statins[J]. Drug Evaluat Res 2024, 47( 5): 941- 950. DOI: 10.7501/j.issn.1674-6376.2024.05.004.

    李智, 魏栋, 万梅绪, 等. 他汀类药物致药物性肝损伤的研究进展[J]. 药物评价研究, 2024, 47( 5): 941- 950. DOI: 10.7501/j.issn.1674-6376.2024.05.004.
    [3]
    AYADA I, VAN KLEEF LA, ZHANG H, et al. Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study[J]. EBioMedicine, 2023, 87: 104392. DOI: 10.1016/j.ebiom.2022.104392.
    [4]
    GAO X, NAN Y, ZHAO YL, et al. Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2017, 1862( 12): 1512- 1519. DOI: 10.1016/j.bbalip.2017.09.007.
    [5]
    WANG XB, CAI BS, YANG XM, et al. Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis[J]. Cell Metab, 2020, 31( 5): 969- 986. e 7. DOI: 10.1016/j.cmet.2020.03.010.
    [6]
    CERDA A, BORTOLIN RH, MANRIQUEZ V, et al. Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells[J]. Pharmacol Rep, 2021, 73( 3): 868- 880. DOI: 10.1007/s43440-021-00241-3.
    [7]
    ZHANG WW, YANG XX, CHEN YL, et al. Activation of hepatic Nogo-B receptor expression-a new anti-liver steatosis mechanism of statins[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2018, 1863( 2): 177- 190. DOI: 10.1016/j.bbalip.2017.12.002.
    [8]
    DEHNAVI S, KIANI A, SADEGHI M, et al. Targeting AMPK by statins: A potential therapeutic approach[J]. Drugs, 2021, 81( 8): 923- 933. DOI: 10.1007/s40265-021-01510-4.
    [9]
    LASTUVKOVA H, FARADONBEH FA, SCHREIBEROVA J, et al. Atorvastatin modulates bile acid homeostasis in mice with diet-induced nonalcoholic steatohepatitis[J]. Int J Mol Sci, 2021, 22( 12): 6468. DOI: 10.3390/ijms22126468.
    [10]
    INIA JA, STOKMAN G, PIETERMAN EJ, et al. Atorvastatin attenuates diet-induced non-alcoholic steatohepatitis in APOE*3-leiden mice by reducing hepatic inflammation[J]. Int J Mol Sci, 2023, 24( 9): 7818. DOI: 10.3390/ijms24097818.
    [11]
    NABIH ES, EL-KHARASHI OA. Targeting HMGB1/TLR4 axis and miR-21 by rosuvastatin: Role in alleviating cholestatic liver injury in a rat model of bile duct ligation[J]. Naunyn Schmiedebergs Arch Pharmacol, 2019, 392( 1): 37- 43. DOI: 10.1007/s00210-018-1560-y.
    [12]
    GONG J, TU W, LIU J, et al. Hepatocytes: A key role in liver inflammation[J]. Front Immunol, 2022, 13: 1083780. DOI: 10.3389/fimmu.2022.1083780.
    [13]
    RODRIGUES G, MOREIRA AJ, BONA S, et al. Simvastatin reduces hepatic oxidative stress and endoplasmic reticulum stress in nonalcoholic steatohepatitis experimental model[J]. Oxid Med Cell Longev, 2019, 2019: 3201873. DOI: 10.1155/2019/3201873.
    [14]
    PARK HS, JANG JE, KO MS, et al. Statins increase mitochondrial and peroxisomal fatty acid oxidation in the liver and prevent non-alcoholic steatohepatitis in mice[J]. Diabetes Metab J, 2016, 40( 5): 376- 385. DOI: 10.4093/dmj.2016.40.5.376.
    [15]
    PEREIRA ENGDS, ARAUJO BP, RODRIGUES KL, et al. Simvastatin improves microcirculatory function in nonalcoholic fatty liver disease and downregulates oxidative and ALE-RAGE stress[J]. Nutrients, 2022, 14( 3): 716. DOI: 10.3390/nu14030716.
    [16]
    MARINHO TS, KAWASAKI A, BRYNTESSON M, et al. Rosuvastatin limits the activation of hepatic stellate cells in diet-induced obese mice[J]. Hepatol Res, 2017, 47( 9): 928- 940. DOI: 10.1111/hepr.12821.
    [17]
    MARRONE G, MAESO-DÍAZ R, GARCÍA-CARDENA G, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins[J]. Gut, 2015, 64( 9): 1434- 1443. DOI: 10.1136/gutjnl-2014-308338.
    [18]
    KITSUGI K, NORITAKE H, MATSUMOTO M, et al. Simvastatin inhibits hepatic stellate cells activation by regulating the ferroptosis signaling pathway[J]. Biochim Biophys Acta Mol Basis Dis, 2023, 1869( 7): 166750. DOI: 10.1016/j.bbadis.2023.166750.
    [19]
    BRAVO M, RAURELL I, HIDE D, et al. Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH[J]. Sci Rep, 2019, 9( 1): 20183. DOI: 10.1038/s41598-019-56366-2.
    [20]
    CHONG LW, HSU YC, LEE TF, et al. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells[J]. BMC Gastroenterol, 2015, 15: 22. DOI: 10.1186/s12876-015-0248-8.
    [21]
    ELBASET MA, MOHAMED BMSA, HESSIN A, et al. Nrf2/HO-1, NF-κB and PI3K/Akt signalling pathways decipher the therapeutic mechanism of pitavastatin in early phase liver fibrosis in rats[J]. J Cell Mol Med, 2024, 28( 3): e18116. DOI: 10.1111/jcmm.18116.
    [22]
    IOANNOU GN, VAN ROOYEN DM, SAVARD C, et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH[J]. J Lipid Res, 2015, 56( 2): 277- 285. DOI: 10.1194/jlr.M053785.
    [23]
    MEIRELES CZ, PASARIN M, LOZANO JJ, et al. Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to hemorrhage/resuscitation[J]. Shock, 2017, 47( 3): 370- 377. DOI: 10.1097/SHK.0000000000000734.
    [24]
    RELJA B, LEHNERT M, SEYBOTH K, et al. Simvastatin reduces mortality and hepatic injury after hemorrhage/resuscitation in rats[J]. Shock, 2010, 34( 1): 46- 54. DOI: 10.1097/SHK.0b013e3181cd8d05.
    [25]
    MURA VL, PASARÍN M, MEIRELES CZ, et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction[J]. Hepatology, 2013, 57( 3): 1172- 1181. DOI: 10.1002/hep.26127.
    [26]
    LI YR, WANG M, HE FL, et al. Etiological and non-etiological therapies for cirrhotic portal hypertension[J]. J Clin Hepatol, 2022, 38( 6): 1224- 1228. DOI: 10.3969/j.issn.1001-5256.2022.06.003.

    李悦榕, 王民, 何福亮, 等. 肝硬化门静脉高压的病因和非病因治疗[J]. 临床肝胆病杂志, 2022, 38( 6): 1224- 1228. DOI: 10.3969/j.issn.1001-5256.2022.06.003.
    [27]
    HIDE D, GIL M, ANDRADE F, et al. Simvastatin-loaded polymeric micelles are more effective and less toxic than conventional statins in a pre-clinical model of advanced chronic liver disease[J]. Nanomed-Nanotechnol Biol Med, 2020, 29: 102267. DOI: 10.1016/j.nano.2020.102267.
    [28]
    SCHIERWAGEN R, MAYBÜCHEN L, HITTATIYA K, et al. Statins improve NASH via inhibition of RhoA and Ras[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 311( 4): G724- G733. DOI: 10.1152/ajpgi.00063.2016.
    [29]
    TRIPATHI DM, VILASECA M, LAFOZ E, et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension[J]. Gastroenterology, 2018, 155( 5): 1564- 1577. DOI: 10.1053/j.gastro.2018.07.022.
    [30]
    LI LZ, ZHAO ZM, ZHANG L, et al. Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway[J]. J Appl Toxicol, 2019, 39( 10): 1394- 1404. DOI: 10.1002/jat.3825.
    [31]
    BENHAMMOU JN, QIAO B, KO A, et al. Lipophilic statins inhibit YAP coactivator transcriptional activity in HCC cells through Rho-mediated modulation of actin cytoskeleton[J]. Am J Physiol Gastrointest Liver Physiol, 2023, 325( 3): G239- G250. DOI: 10.1152/ajpgi.00089.2023.
    [32]
    RIDRUEJO E, ROMERO-CAÍMI G, OBREGÓN MJ, et al. Potential molecular targets of statins in the prevention of hepatocarcinogenesis[J]. Ann Hepatol, 2018, 17( 3): 490- 500. DOI: 10.5604/01.3001.0011.7394.
    [33]
    LIU PC, LU G, DENG Y, et al. Inhibition of NF-κB pathway and modulation of MAPK signaling pathways in glioblastoma and implications for lovastatin and tumor necrosis factor-related apoptosis inducing ligand(TRAIL) combination therapy[J]. PLoS One, 2017, 12( 1): e0171157. DOI: 10.1371/journal.pone.0171157.
    [34]
    GHALALI A, MARTIN-RENEDO J, HÖGBERG J, et al. Atorvastatin decreases HBx-induced phospho-akt in hepatocytes via P2X receptors[J]. Mol Cancer Res, 2017, 15( 6): 714- 722. DOI: 10.1158/1541-7786.MCR-16-0373.
    [35]
    D’SOUZA S, LAU KC, COFFIN CS, et al. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma[J]. World J Gastroenterol, 2020, 26( 38): 5759- 5783. DOI: 10.3748/wjg.v26.i38.5759.
    [36]
    FRANCIS P, FORMAN LM. Statins show promise against progression of liver disease[J]. Clin Liver Dis, 2021, 18( 6): 280- 287. DOI: 10.1002/cld.1143.
    [37]
    FENG J, DAI WQ, MAO YQ, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis[J]. J Exp Clin Cancer Res, 2020, 39( 1): 24. DOI: 10.1186/s13046-020-1528-x.
    [38]
    KIM GW, IMAM H, KHAN M, et al. HBV-induced increased N6 methyladenosine modification of PTEN RNA affects innate immunity and contributes to HCC[J]. Hepatology, 2021, 73( 2): 533- 547. DOI: 10.1002/hep.31313.
    [39]
    IVANOV AV, VALUEV-ELLISTON VT, TYURINA DA, et al. Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis[J]. Oncotarget, 2017, 8( 3): 3895- 3932. DOI: 10.18632/oncotarget.13904.
    [40]
    KIM MH, KIM MY, SALLOUM S, et al. Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature[J]. Hepatol Commun, 2022, 6( 9): 2581- 2593. DOI: 10.1002/hep4.1991.
    [41]
    YANG YH, CHEN WC, TSAN YT, et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection[J]. J Hepatol, 2015, 63( 5): 1111- 1117. DOI: 10.1016/j.jhep.2015.07.006.
    [42]
    LIANG YJ, SUN CP, HSU YC, et al. Statin inhibits large hepatitis delta antigen-Smad3-twist-mediated epithelial-to-mesenchymal transition and hepatitis D virus secretion[J]. J Biomed Sci, 2020, 27( 1): 65. DOI: 10.1186/s12929-020-00659-6.
    [43]
    FATIMA K, MOEED A, WAQAR E, et al. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2022, 46( 4): 101816. DOI: 10.1016/j.clinre.2021.101816.
    [44]
    VELL MS, LOOMBA R, KRISHNAN A, et al. Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality[J]. JAMA Netw Open, 2023, 6( 6): e2320222. DOI: 10.1001/jamanetworkopen.2023.20222.
    [45]
    WONG YJ, QIU TY, NG GK, et al. Efficacy and safety of statin for hepatocellular carcinoma prevention among chronic liver disease patients: A systematic review and meta-analysis[J]. J Clin Gastroenterol, 2021, 55( 7): 615- 623. DOI: 10.1097/MCG.0000000000001478.
    [46]
    MEURER L, COHEN SM. Drug-induced liver injury from statins[J]. Clin Liver Dis, 2020, 24( 1): 107- 119. DOI: 10.1016/j.cld.2019.09.007.
    [47]
    BENES LB, BASSI NS, DAVIDSON MH. The risk of hepatotoxicity, new onset diabetes and rhabdomyolysis in the era of high-intensity statin therapy: Does statin type matter?[J]. Prog Cardiovasc Dis, 2016, 59( 2): 145- 152. DOI: 10.1016/j.pcad.2016.08.001.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (127) PDF downloads(20) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return